Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2225 in Systemic Sclerosis
NCT04948554Phase 1Terminated
- Start
- Mar 2023
- Primary completion
- Oct 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of ACE-1334 in systemic sclerosis (SSc) (12 cohorts). Primary endpoints: Number of Participants with ≥1 Adverse Event at 20 weeks and Number of Participants Discontinuing from Study Therapy Due to AE at 12 weeks. Started Mar 2023; status: terminated.
02
Drugs
ACE-1334
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT04948554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948554.